

The NCI's PREVENT Cancer Preclinical Drug Development Program: Overview, Current Projects, Animal Models, Agent Development Strategies, and Molecular Targets

Robert H. Shoemaker PhD, Chen S. Suen PhD, Cathy A. Holmes PhD, Judith R. Fay MS, Vernon E. Steele PhD, MPH



PII: S0093-7754(15)00173-6
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2015.09.008>
Reference: YSONC51864

To appear in: *Semin Oncol*

Cite this article as: Robert H. Shoemaker PhD, Chen S. Suen PhD, Cathy A. Holmes PhD, Judith R. Fay MS, Vernon E. Steele PhD, MPH, The NCI's PREVENT Cancer Preclinical Drug Development Program: Overview, Current Projects, Animal Models, Agent Development Strategies, and Molecular Targets, *Semin Oncol*, <http://dx.doi.org/10.1053/j.seminoncol.2015.09.008>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The NCI's PREVENT Cancer Preclinical Drug Development Program: Overview,
Current Projects, Animal Models, Agent Development Strategies, and Molecular Targets
Authors: Robert H. Shoemaker, PhD^{1,2}, Chen S. Suen, PhD¹, Cathy A. Holmes, PhD³,
Judith R. Fay, MS³, and Vernon E. Steele, PhD, MPH¹

¹Chemopreventive Agent Development Research Group, Division of Cancer Prevention,
National Cancer Institute, National Institutes of Health

²Corresponding Author: Robert H. Shoemaker, Ph.D., 9609 Medical Center Drive Room
5E452, MSC 9787, Bethesda, MD 20892
Phone (240) 276-7077, FAX (240) 276-7847
Email: Shoemakr@mail.nih.gov

³CCS Associates, Inc., 1923 Landings Drive, Mountain View, CA 94043

There are no direct financial interests in the subject matter or products discussed herein.

ABSTRACT

The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a
National Cancer Institute, Division of Cancer Prevention (NCI, DCP)-supported program
whose primary goal is to bring new cancer preventive interventions (small molecules and
vaccines) and biomarkers through preclinical development towards clinical trials by
creating partnerships between the public sector (*e.g.*, academia, industry) and DCP.
PREVENT has a formalized structure for moving interventions forward in the prevention
pipeline using a stage-gate process with go/no go decision points along the critical path
for development. This review describes the structure of the program, its focus areas, and
provides examples of projects currently in the pipeline.

Download English Version:

<https://daneshyari.com/en/article/10924305>

Download Persian Version:

<https://daneshyari.com/article/10924305>

[Daneshyari.com](https://daneshyari.com)